Entries by primitus

Lead Software Developer

Engitix uses proprietary decellularisation technologies to expand cells in 3D culture. Unlike traditional decellularisation technologies which generate extracellular matrix (ECM) products from animal tissue, the Engitix 3D Tissue Engineering System produces human ECM scaffolds which retain the biophysical and biochemical properties of the healthy or diseased donor organ ECM. These ECM scaffolds are then used […]

Software Developer

Engitix uses proprietary decellularisation technologies to expand cells in 3D culture. Unlike traditional decellularisation technologies which generate extracellular matrix (ECM) products from animal tissue, the Engitix 3D Tissue Engineering System produces human ECM scaffolds which retain the biophysical and biochemical properties of the healthy or diseased donor organ ECM. These ECM scaffolds are then used […]

Lab Support Technician

Engitix uses proprietary decellularisation technologies to expand cells in 3D culture. Unlike traditional decellularisation technologies which generate extracellular matrix (ECM) products from animal tissue, the Engitix 3D Tissue Engineering System produces human ECM scaffolds which retain the biophysical and biochemical properties of the healthy or diseased donor organ ECM. These ECM scaffolds are then used […]

Engitix Therapeutics appoints Dr Mike Burbridge as VP Oncology and Immuno-oncology

London, UK – 4 May 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology. Dr […]

Scientist/Sr Scientist (molecular and cell biology – target validation)

Engitix Ltd, a privately-owned biopharmaceutical company, is seeking a full-time Scientist to join our multi-disciplinary team. Applicants are expected to be self-starters, team players and comfortable working in a dynamic, fast-paced, creative, entrepreneurial environment. Engitix uses proprietary decellularisation technologies to expand cells in 3D culture. Unlike traditional decellularisation technologies which generate extracellular matrix (ECM) products […]

Scientist/Sr Scientist, Drug Discovery (assay development and screening)

Engitix Ltd, a privately-owned biopharmaceutical company, is seeking a full-time Scientist to join our multi-disciplinary team. Applicants are expected to be self-starters, team players and comfortable working in a dynamic, fast-paced, creative, entrepreneurial environment. Engitix uses proprietary decellularisation technologies to expand cells in 3D culture. Unlike traditional decellularisation technologies which generate extracellular matrix (ECM) products […]

Engitix Therapeutics strengthens management team with new directors for fibrosis and computational biology

Company is on expansion curve with two new appointments and recent move to larger facilities London, UK – 23 Feb, 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today […]

Scientist, Oncology research

Engitix Ltd, a privately-owned biopharmaceutical company, is seeking a full-time Scientist to join our multi-disciplinary team. Applicants are expected to be self-starters, team players and comfortable working in a dynamic, fast-paced, creative and entrepreneurial environment. Engitix uses proprietary decellularization technologies to expand cells in 3D culture. Unlike traditional decellularization technologies, which generate extracellular matrix (ECM) […]

Engitix Therapeutics to relocate headquarters to new life sciences cluster, White City Place

London, UK – December 15, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP). The move follows […]

Engitix Appoints Eduardo Bravo as Chairman of its Board of Directors

London, UK – December 1, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based upon its proprietary human extracellular matrix (ECM) platform, today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors. Eduardo has over 25 years […]